Search PubMed⌕ Search

Biomedical subjects

T Trnovec

Publications and source records attributed to T Trnovec.

124 records · Page 7Linked to original sources
PubMedDate not supplied

Pharmacokinetics of carbisocaine in rats and mice.

[14C]carbisocaine, N-(2-(2-[1-14C]-heptyloxyphenylcarbamoyloxy)-propyl)-diethylammoni um chloride was administered to male Wistar rats, weighing 180-210 g IV in doses of 0.425, 1.425, 2.425 or 4.425 mg/kg or orally in a dose of 2.425 mg/kg. Extraction of carbisocaine from alkaline media into n-heptane was used for assessment of the unchanged drug in plasma, organs and excreta in predetermined time intervals. The two-way analysis of variance confirmed the insignificant effect of subject variability of experimental animals (p greater than 0.05) on plasma data after IV administration. Plasma data following the IV administration were approximated by a linear open two-compartment model with elimination from the central compartment. Regression analysis indicated linearity between carbisocaine plasma AUC and the IV administered dose within the range tested. The following model parameters were obtained: elimination half-life 161.2 +/- 37.5 min, total body clearance 59.5 ml/min/kg, distribution volume in steady state 5616.2 ml/kg and mean residence time 96.7 min. The systemic availability of the orally given carbisocaine was 45.2%, assessed by AUCpo/AUCiv (0-360 min). The brain uptake index of carbisocaine in relation to 3H2O was 57.7 +/- 3.9%. Whole body autoradiographs of mice injected with [14C]carbisocaine documented accumulation of 14C in gall and urinary bladder and in the gut contents and the effective placental barrier against carbisocaine and its metabolites.

Anesthetics, Local↗
PubMedDate not supplied

Pharmacokinetics of heptacaine, a novel potent local anaesthetic agent, after rectal administration to rats.

The pharmacokinetics of heptacaine, N-(2-(2-heptyloxyphenylcarbamoyloxy)ethyl)-piperidinium chloride, a new long-acting potent carbanilate type local anaesthetic, proposed for local anaesthesia in complex treatment of hemorrhoids, was studied following its rectal administration to rats in the form of cocoa butter suppositories. The heptacaine plasma concentration, 0.0083% of dose/ml, peaked at 90 min post administration and the maximum rate of its bioavailability, 0.19% of dose/min, assessed by deconvolution, occurred 38 min post administration. The plasma elimination half-life of heptacaine was 133 min and its biological availability of 52% was comparable to other agents of the class.

Administration, Rectal↗
PubMedDate not supplied

The effect of two glucan carboxymethyl derivatives with various substitution degrees on cyclophosphamide immunosuppression in mice.

Carboxymethylglucan (CMG) in two different degrees of substitution of carboxymethyl groups (0.56 and 0.89) was administered to cyclophosphamide (CY) treated (200 mg/kg) C57B1/6 mice in three doses (10, 50, and 100 mg/kg) 24 h after CY. The influence of CMG administration on the cell suppression caused by CY was observed in the subsequent days. The cellularity of spleen, bone marrow and peripheral blood was quantified on days 2, 5, 8, 11, 15, and 21 after CY treatment. CY treated mice developed a significant decrease in peripheral blood cell counts, and spleen and bone marrow cellularity during the initial 5 days, followed by recovery in the next 15 days, with an overshoot reaction in spleen cellularity and erythrocyte levels. The initial cellularity depression and the following recovery was modified by both carboxymethyl derivatives of glucan. Cyclophosphamide treated mice exhibited less pronounced immunosuppression and more rapid hematopoietic recovery when administered with CMG, although this reaction was only of a modest degree. The effects were not dose dependent and the differences between the two glucans were not significant.

Animals↗
PubMedDate not supplied

Disposition of ethimizol, a xanthine-related nootropic drug, in perfused rat liver and isolated hepatocytes.

Ethimizol, 4,5-di(methylcarbamoyl)-1-ethyl-imidazole, was metabolized into at least six metabolites in an isolated perfused rat liver preparation. Based on TLC and mass spectrometry, 4-carbamoyl-5-methylcarbamoyl-1-ethyl-imidazole and 4,5-di(methylcarbamoyl)-imidazole were identified as the primary metabolites of ethimizol. These undergo further biotransformation: both can form 4(5)-carbamoyl-5(4)-methylcarbamoyl-imidazole, and, moreover, the former can be hydroxylated. Besides the identified metabolites, two polar ones of unknown structure were detected. Dose-dependent elimination of ethimizol was observed when the drug was added to the liver perfusion recirculating medium in initial reservoir concentrations of 39, 48, 85, 165, and 240 microM. The observed nonlinearity appeared to be a result of a competitive product inhibition. Similar to the parent drug, ethimizol primary metabolites were formed and eliminated in a dose-dependent manner. The uptake of ethimizol by isolated hepatocytes was extremely rapid, independent of drug concentration, over the range 0 to 250 microM, unaffected by inhibitors and independent of temperature.

Animals↗
PubMedDate not supplied

The effect of enzyme induction and inhibition on the disposition of the xanthine-related nootropic drug ethimizol in perfused liver and hepatocytes of rats.

The once-through perfused (18 ml/min) rat liver preparations from vehicle-, phenobarbital (PB)-, and 3-methylcholanthrene (3-MC)-treated rats were used for the study of 14C-ethimizol [4,5-di(methylcarbamoyl)-1-ethyl-imidazole] elimination after input concentrations of 5, 25, 50, and 100 microM. The steady state hepatic extraction ratios decreased with increasing ethimizol inputs and were (mean +/- SD): for vehicle-treated rats, 0.361 +/- 0.038, 0.193 +/- 0.018, 0.141 +/- 0.010, and 0.100 +/- 0.011; for PB-treated rats, 0.578 +/- 0.093, 0.393 +/- 0.039, 0.302 +/- 0.028, and 0.236 +/- 0.032; and for 3-MC-treated rats, 0.913 +/- 0.057, 0.783 +/- 0.130, 0.619 +/- 0.097, and 0.447 +/- 0.053, for the respective concentrations. In recirculating experiments both PB and 3-MC increased ethimizol elimination, but the effect of the latter was considerably greater. 3-MC was also more effective than PB in enhancing the rate of formation and subsequent biotransformation of the primarily formed ethimizol metabolites, 4-carbamoyl-1-ethyl-5-methylcarbamoyl-imidazole and 4,5-di(methylcarbamoyl)-imidazole. Elimination of ethimizol was inhibited in suspension of rat hepatocytes by SKF 525-A at concentrations of 10 and 100 microM by 63% and 60%, respectively, and by alpha-naphthoflavone, at the same concentrations, by 71% and 85%, respectively. Their simultaneous addition almost completely inhibited ethimizol biotransformation. An increase of the ethimizol elimination rate in single-pass rat liver perfusion by 55% was observed in preparations from rats treated by ethimizol in their drinking water, whereas the liver/body weight ratio, microsomal protein, and cytochrome P-450 content remained unaffected.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMedDate not supplied

Disposition of ethimizol, a nootropic drug, in rats and mice.

The pharmacokinetics of ethimizol, a nootropic drug, were studied in rats and mice using [2-14C]-4,5-di(methylcarbamoyl)-1-ethyl-imidazole. Autoradiography in mice injected iv showed a rapid and homogeneous distribution of the label into the tissues, brain included, and its excretion by the urinary pathway. The determination of ethimizol in plasma, organs, and excreta was based on combined extraction and the TLC procedure. In rats, the elimination half-life of ethimizol after iv administration of 10 mg/kg was 25 min, and its distribution volume was 1.4 liters/kg. The tissue/plasma concentration ratio for organs investigated was 1 immediately after iv administration, with a subsequent gradual increase. Based on this, saturable tissue binding of ethimizol in the liver, kidney, and brain was suggested. The drug was almost completely absorbed after administration, yet its systemic availability was only 32%. The brain uptake index of ethimizol was 101% as compared to 3H2O. Ethimizol was eliminated by metabolism. The labeled metabolites were predominantly excreted in the urine.

Animals↗
PubMedDate not supplied

Disposition of exaprolol, a new beta-blocker, in rats.

Pharmacokinetics of tritium-labeled exaprolol, 1-(2-cyclohexyl[2,4-3H]-3-isopropylamino-2-propanol, a potent beta-adrenergic blocker, was studied in rats. The assay of the parent drug in plasma and excreta was based on extraction into toluene and TLC. In rats elimination half-lives of exaprolol after iv and oral administration of 26.8 and 40.1 hr, respectively, were found; the bioavailability was 26.7%. After oral administration to rats, the drug was rapidly and completely absorbed. The long retention of exaprolol in tissues of iv injected rats was reflected by the steady-state distribution volume of 59.38 liters/kg and the clearance rate of 1.44 liters/hr/kg. The total 3H excreted in urine within 96 hr after iv or oral administration to rats amounted to 47.9 and 47.1% of dose, respectively, and in feces to 34.2 and 29.8%, respectively. The ratio of 3H-exaprolol to total 3H concentration in plasma, urine, and feces of rats indicated a moderately extensive metabolism of the parent drug. The substance was about 50% bound to human serum albumin. The rat erythrocyte/plasma partition coefficient rose with exaprolol concentration.

Animals↗
PubMedDate not supplied

Pharmacokinetics of gentamicin administered intratracheally or as an inhalation aerosol to guinea pigs.

The pharmacokinetics of gentamicin were studied after intratracheal, inhalation, and iv administration to guinea pigs. Gentamicin injected intratracheally was almost completely systemically available. The comparison of the gentamicin plasma AUCs after inhalation and iv administration showed that an inhalation exposure lasting 10 min resulted in an absorption of 1.13 mg gentamicin/kg body weight into systemic circulation. This absorbed dose was 40.4 or 67.3% of the amount of gentamicin inhaled, depending on tidal volume assumed, and 1.4% of the amount of gentamicin aerosolized. The postinhalation gentamicin concentration in the lungs decreased with a half-life of 67.3 min. The data differentiate topical pulmonary gentamicin from systemic gentamicin and give a rational basis for study of the mechanism of the therapeutic effect of gentamicin inhalation aerosol in bronchopulmonary infections.

Aerosols↗
PubMedDate not supplied

Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling.

The pharmacokinetics of acetylsalicylic acid (ASA) and its metabolites salicylic acid (SA) and salicyluric acid (SUA) were studied in 12 healthy young volunteers after oral administration of low (30 and 100 mg) and moderate (400 mg) doses. Plasma and urine were assayed for the above drugs by high-performance liquid chromatographic method. Individual pharmacokinetic parameters were estimated by compartmental modeling (ASA and SA) and by model-independent methods (SUA). ASA parameter values estimated in this study were in agreement with those reported by other authors after administration of higher doses, which confirms the linearity of ASA pharmacokinetics in a broad dose range. On the contrary, both metabolic and renal elimination routes for SA were found to be saturable. The relative changes in SA renal clearance with the dose were more pronounced than those in metabolic clearance. Particularly, there was no statistically significant difference in SA metabolic clearance between 30 and 100 mg doses, indicating the linear kinetics in this dose range. Further increase in the dose resulted in significant decrease in SA metabolic clearance. At the same time, both SA excretion rate constant and fraction excreted significantly diminished across the entire dose range studied. The dependence of SUA renal clearance upon the dose was shown to be complex, reflecting possible saturability of its excretion.

Administration, Oral↗
PubMedDate not supplied

[The prediction of enantiomeric differences in the pharmacokinetic parameters of drugs by using a physiological perfusion model].

A physiological perfusion pharmacokinetic model was used to assess the possible differences in the model-independent pharmacokinetic parameters of drug enantiomers (total clearance, mean retention time, half-life and stationary distribution volume), depending on differences in their blood binding and in the values of intrinsic hepatic clearance. The distribution in the organs and tissues and renal clearance of enantiomers were assumed to be equal. The maximally possible values of the relationships of the above parameters were found for enantiomers. The relative values of parameters vary irregularly with the increase in the values of intrinsic hepatic clearance: drastic changes occur in the range 0 to 100 liter/hour, but they do not take place in the range 100 to 1000 liter/hour. The differences in enantiomeric parameters also decrease as the blood binding of enantiomers drops.

Forecasting↗
PubMedDate not supplied

On the absorption of drugs using chronic dog ileal loop method.

The absorption rate of three model drugs, i.e., pentacaine (highly lipophilic), stobadine (moderately lipophilic) and acetylsalicylic acid (hydrophilic), was studied using the chronic dog ileal loop method. The drugs were dissolved either in 0.9% unbuffered solution of NaCl or in antacid mixture. When using 0.9% NaCl, the half-lives of absorption (t1/2 (dis)) of pentacaine and stobadine were (mean +/- SD) 23.2 +/- 7.8 min and 20.8 +/- 7.2 min, respectively. For stobadine a good agreement was found between its t1/2 (dis) from the ileum and its absorption half-life determined from blood concentrations after oral administration to dogs. The absorption of acetylsalicylic acid accounted for only 10-20% of the dose introduced into the loop over 45 min; thus, a reliable value of t1/2 (dis) could not be determined. The administration of unbuffered solution of NaCl into the loop was accompanied by rapid increase of pH from acidic to basic value. The antacid mixture failed to affect the absorption rate of the drugs studied. Sampling from the ileum was limited to 35-55 min due to rapid absorption of water. These results suggest that: 1) measurement of the absorption rate of some drugs, e.g., stobadine, by using the chronic dog ileal loop method may adequately predict their absorption rate after peroral administration to the dog, 2) interactions of antacids with drug absorption in the ileum may not play a significant role because of the strong buffering capacity of the ileum, and 3) rapid absorption of water from the ileum does not allow to reliably determine the value of t1/2 (dis) for slowly absorbed drugs.

Administration, Oral↗